THE UNBEARABLE LIGHTNESS OF PRESCRIBING GROWTH HORMONE

L. Šaranac
{"title":"THE UNBEARABLE LIGHTNESS OF PRESCRIBING GROWTH HORMONE","authors":"L. Šaranac","doi":"10.22190/FUMB190119001S","DOIUrl":null,"url":null,"abstract":"Short stature is the most visible and prominent physical characteristic and one of the commonest reason for referral to pediatric endocrinologist. It is assumed as disabling condition with psychosocial consequences that seeks treatment. Behind short stature severe pathology could be hidden, although not necessarily of endocrine origin. Even in the new millennium, many diagnostic pitfalls and dilemmas persist in confirmation of growth hormone deficiency (GHD), the first indication that fits in endocrine paradigm: to replace the missing hormone. In 1985 FDA approved recombinant human GH (hGH) as the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous GH. Availability of hGH in unlimited amounts enhanced the number of indications of GH use. Pediatric endocrinologist started to promote and to apply use of hGH for height in short, but otherwise healthy children, with hormonal normalcy. Reasonable criticism of such praxis arises in the light of recent safety alerts. The unbearable lightness of prescribing growth hormone to every apparently or really short child is reaching epidemic progress in Serbia. When authorities in this low income country (estimated as developing), approved hGH for use in SGA (small for gestational age) children, use and misuse of hGH exploded. Socially acceptable height, the term applied by some endocrinologists actually means that society does not accept short people. The pharmaceutical companies go even further offering, besides growth acceleration, better and brighter future for potential patients, in whom the self-confidence is measured by centimeters of height. However, benefits of such treatment on quality of life were never confirmed. Children with severe growth failure and documented GHD should be treated undoubtedly, but use of hGH for height, so called cosmetic endocrinology, needs critical appraisal. Children and their parents should be informed about height prediction and long-term consequences.","PeriodicalId":167216,"journal":{"name":"Facta Universitatis, Series: Medicine and Biology","volume":"122 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Facta Universitatis, Series: Medicine and Biology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22190/FUMB190119001S","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3

Abstract

Short stature is the most visible and prominent physical characteristic and one of the commonest reason for referral to pediatric endocrinologist. It is assumed as disabling condition with psychosocial consequences that seeks treatment. Behind short stature severe pathology could be hidden, although not necessarily of endocrine origin. Even in the new millennium, many diagnostic pitfalls and dilemmas persist in confirmation of growth hormone deficiency (GHD), the first indication that fits in endocrine paradigm: to replace the missing hormone. In 1985 FDA approved recombinant human GH (hGH) as the treatment of pediatric patients who have growth failure due to inadequate secretion of endogenous GH. Availability of hGH in unlimited amounts enhanced the number of indications of GH use. Pediatric endocrinologist started to promote and to apply use of hGH for height in short, but otherwise healthy children, with hormonal normalcy. Reasonable criticism of such praxis arises in the light of recent safety alerts. The unbearable lightness of prescribing growth hormone to every apparently or really short child is reaching epidemic progress in Serbia. When authorities in this low income country (estimated as developing), approved hGH for use in SGA (small for gestational age) children, use and misuse of hGH exploded. Socially acceptable height, the term applied by some endocrinologists actually means that society does not accept short people. The pharmaceutical companies go even further offering, besides growth acceleration, better and brighter future for potential patients, in whom the self-confidence is measured by centimeters of height. However, benefits of such treatment on quality of life were never confirmed. Children with severe growth failure and documented GHD should be treated undoubtedly, but use of hGH for height, so called cosmetic endocrinology, needs critical appraisal. Children and their parents should be informed about height prediction and long-term consequences.
开具生长激素处方时难以忍受的轻量
身材矮小是最明显和最突出的身体特征,也是转介给儿科内分泌学家的最常见原因之一。它被认为是一种具有社会心理后果的致残状况,需要寻求治疗。身材矮小的背后可能隐藏着严重的病理,尽管不一定是内分泌的原因。即使在新的千年里,在确认生长激素缺乏症(GHD)时,仍然存在许多诊断陷阱和困境,这是符合内分泌范式的第一个迹象:替代缺失的激素。1985年,FDA批准重组人生长激素(hGH)用于治疗由于内源性生长激素分泌不足而导致生长衰竭的儿科患者。无限量的生长激素的可用性增加了生长激素使用的适应症。儿科内分泌学家开始推广并应用生长激素用于身高,但其他方面健康的儿童,激素正常。鉴于最近的安全警报,对这种做法提出了合理的批评。在塞尔维亚,给每一个明显或确实矮小的孩子开生长激素的难以忍受的轻疾性正在蔓延。当这个低收入国家(估计为发展中国家)的当局批准hGH用于SGA(小于胎龄)儿童时,hGH的使用和滥用激增。社会可接受的身高,这个词被一些内分泌学家使用,实际上是指社会不接受矮个子。制药公司甚至更进一步,为那些以身高为衡量标准的潜在患者提供了除了增长加速之外更美好、更光明的未来。然而,这种治疗对生活质量的好处从未得到证实。患有严重生长衰竭和记录在案的生长发育障碍的儿童无疑应该接受治疗,但使用生长发育障碍来测量身高,也就是所谓的美容内分泌学,需要进行严格的评估。孩子和他们的父母应该被告知身高预测和长期后果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信